A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

Abstract Objectives To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double‐negative T cells (CD19‐CAR‐DNTs) as an off‐the‐shelf therapeutic cell product. Methods A membrane proteome array was used to assess the off‐target binding of CD19‐CAR. DNTs...

Full description

Saved in:
Bibliographic Details
Main Authors: Dan Wang, Liuyang Wang, Shuai Liu, Jianjun Tong, Honglin Zhu, Man Xu, Xiancai Li, Zhiqiang Xiang, Qinghua Sun, Hengcai Wang, Yuli Wang, Shuyang Wang, Liming Yang
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Clinical & Translational Immunology
Subjects:
allogeneic CD19‐CAR‐DNTs
B‐cell malignancies
cytotoxicity and safety
off‐the‐shelf immunotherapy
Online Access:https://doi.org/10.1002/cti2.70022
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cti2.70022

Similar Items